Host Response Mediators in Coronavirus (COVID-19) Infection

Summary

The coronavirus (COVID-19) pandemic continues to grow exponentially. Angiotensin II levels are increased in human influenza and are associated with influenza viral load, disease progression and mortality. Preliminary data shows angiotensin II receptor blockers (ARBs) limits lung injury in murine influenza H7N9, as well as viral titre and RNA. ARBs could limit viral titre and organ injury in COVID-19. We will therefore collect clinical chart data and test angiotensin II levels of patients who are admitted to ICU with COVID-19 to determine whether there is a correlation between taking ARBs and clinical outcomes in these patients.

Other blood biomarkers and clinical risk factors for COVID-19 have come to light in recent weeks. We include these in our observational analysis to help generate an understanding of COVID-19 presentation and blood biomarker characterization of disease.

Conditions

• COVID-19
• SARS-CoV2

Interventions

OTHER

ARBs and/or ACE inhibitors

This is an observational study only.

OTHER

Usual Care

This is an observational study only.

Sponsors & Collaborators

• Canadian Institutes of Health Research (CIHR)

  collaborator OTHER_GOV

• British Columbia Centre for Disease Control

  collaborator OTHER_GOV

• McGill University Health Centre/Research Institute of the McGill University Health Centre

  collaborator OTHER

• University of Toronto

  collaborator OTHER

• University of Ottawa

  collaborator OTHER

• University of Calgary

  collaborator OTHER

• University of Alberta

  collaborator OTHER

• University of Victoria

  collaborator OTHER

• Wuhan University

  collaborator OTHER

• Peking Union Medical College

  collaborator OTHER

• University of Pennsylvania

  collaborator OTHER

• University of British Columbia

  lead OTHER

Principal Investigators

• James A Russell, MD · St Paul's Hospital, Center for Heart and Lung Innovation

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-03-17

Primary Completion

2021-06-30

Completion

2022-06-30

Countries

• Canada

Study Locations